YOLFTbeta
Vistin Pharma ASA

Vistin Pharma ASA

VISTN · OL · Healthcare / Drug Manufacturers - Specialty & Generic

19.35NOK+0.15 (+0.78%)

Price History

Full chart

Market Stats

Previous Close19.20
Open19.00
Day Range19.00 – 19.35
52-Week Range17.70 – 22.70
Volume1.27K
Market Cap804.85M
P/E (TTM)11.49
Forward P/E0.00
EPS1.58
Dividend Yield5.48%
Beta0.58
50-Day Avg19.25
200-Day Avg20.74

About

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Magnus Tolleshaug
  • Employees74
  • HeadquartersØstensjøveien 27, Oslo, Norway, 0661, Norway
  • Websitehttps://www.vistin.com

Leadership

  • Mr. Magnus TolleshaugChief Executive Officer
  • Mr. Alexander KarlsenChief Financial Officer
  • Mr. Vegard HeggemChief Operating Officer
  • Ms. Lilly Margareth MyraVice President of Quality
  • Eivind EgeliDirector of Technical Service & Sales

Financials

Income Statement

Currency: NOK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue170.51M176.69M198.99M227.19M253.16M278.62M287.68M435.39M429.09M452.29M
Growth (%)-+3.62%+12.62%+14.17%+11.43%+10.06%+3.25%+51.35%-1.45%+5.41%
Cost of Revenue62.30M97.10M108.53M121.43M110.22M96.10M199.88M233.15M149.97M220.34M
Gross Profit108.21M79.59M90.46M105.75M142.94M182.53M166.80M259.69M279.12M231.95M
Gross Margin63.46%45.04%45.46%46.55%56.46%65.51%57.98%59.64%65.05%51.28%
Operating Expense86.28M65.57M95.07M88.98M97.39M149.28M172.90M191.09M193.83M139.60M
Operating Income21.93M14.02M-4.61M16.77M45.56M33.25M-6.10M68.60M85.30M92.35M
Operating Margin12.86%7.93%-2.32%7.38%18.00%11.93%-2.12%15.76%19.88%20.42%
EBITDA-11.99M-79.79M93.22M-113.83M42.96M8.41M78.13M101.82M120.33M
EBITDA Margin-6.79%-40.10%41.03%-44.96%15.42%2.92%17.95%23.73%26.60%
Net Income12.92M70.40M-73.63M66.20M-96.95M24.95M-4.72M45.60M62.75M74.75M
Net Income Margin7.58%39.84%-37.00%29.14%-38.30%8.96%-1.64%10.47%14.62%16.53%
Interest Expense00165.00K216.00K820.00K357.00K2.14M2.27M2.34M1.96M
Interest Expense % of Total Revenue0.00%0.00%0.08%0.10%0.32%0.13%0.74%0.52%0.54%0.43%

Balance Sheet

Currency: NOK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets279.52M231.75M500.06M504.17M321.92M333.15M407.21M403.40M384.94M439.43M
Total Liabilities92.91M111.59M151.21M90.77M49.51M57.26M133.95M80.63M75.42M110.62M
Total Equity186.61M120.16M348.85M413.40M272.40M275.89M273.26M322.77M309.53M328.81M
Cash79.94M69.38M320.73M319.67M77.04M35.75M1.44M26.20M12.79M16.42M
Net Debt------43.71M---

Cash Flow

Currency: NOK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-53.84M9.51M-39.48M18.93M-145.73M13.68M-8.87M90.59M107.86M78.04M
Investing Cash Flow--16.10M122.93M-22.77M-18.36M-51.38M-31.68M-64.29M-17.68M-40.30M-
Financing Cash Flow--10.23M-136.55M297.65M-1.64M-45.53M-23.30M38.85M-48.14M-80.97M-
Capital Expenditure016.27M35.55M18.07M18.36M53.10M31.94M64.29M17.90M40.80M16.68M
Free Cash Flow---26.04M-57.55M580.00K-198.83M-18.26M-74.80M72.69M67.05M61.35M
Dividends Paid-10.23M17.04M44.34M44.34M44.34M22.17M0077.59M55.43M
FCF to OCF---273.90%145.78%3.06%136.44%-133.46%843.48%80.24%62.17%78.62%
Dividend Paid to FCF---65.43%-77.05%7645.69%-22.30%-121.44%0.00%0.00%115.71%90.35%

Earnings

Report DateAug 26, 2015Oct 29, 2015Feb 23, 2016Apr 28, 2016Aug 30, 2016Oct 31, 2016Feb 28, 2017Apr 26, 2017Aug 31, 2017Oct 27, 2017Feb 27, 2018Apr 26, 2018Aug 30, 2018Oct 25, 2018Feb 19, 2019Apr 25, 2019Aug 29, 2019Oct 25, 2019Feb 28, 2020Apr 23, 2020Aug 28, 2020Oct 30, 2020Feb 19, 2021Apr 23, 2021Aug 19, 2021Oct 28, 2021Feb 17, 2022Apr 27, 2022Aug 19, 2022Oct 26, 2022Feb 17, 2023Apr 27, 2023Aug 23, 2023Oct 25, 2023Feb 16, 2024Apr 24, 2024Aug 23, 2024Oct 31, 2024Feb 14, 2025Apr 25, 2025Jun 30, 2025Oct 31, 2025Dec 31, 2025Apr 24, 2026Aug 20, 2026Oct 29, 2026
EPS Estimate-0.400.450.400.500.400.300.400.490.30-0.100.100.200.10--------------------------------
EPS Actual0.120.530.600.390.570.25-0.460.230.220.33-0.390.34-0.34-0.06-1.370.040.011.340.09-2.950.470.100.190.200.180.020.16-0.340.01-0.150.38-0.070.160.530.410.170.430.370.440.490.420.420.360.480.32-
Surprise-32.50%33.33%-2.50%14.00%-37.50%-253.33%-42.50%-55.10%10.00%-290.00%240.00%-270.00%-160.00%--------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-After-hours-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap804.85M
Enterprise Value816.92M
Trailing P/E11.49
Forward P/E0.00
Price / Sales1.86
Price / Book2.53
EPS1.58
Book Value7.22
Revenue (TTM)432.00M
Gross Profit (TTM)292.07M
EBITDA102.84M
Profit Margin16.25%
Operating Margin16.02%
Return on Equity22.86%
Return on Assets11.64%
Shares Outstanding44.34M
Shares Float20.69M
Beta0.58
Dividend Yield5.48%
Dividend Rate1.00
Payout Ratio63.20%

Dividends

20261×
1.00May 22, 2026
20251×
1.25Jun 4, 2025
20243×
0.50Nov 6, 20240.50Jun 5, 20240.75Jan 23, 2024
20211×
0.50May 21, 2021
20201×
1.00May 20, 2020
20171×
0.98May 26, 2017
20161×
0.59May 25, 2016